| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.1M | — | +10.3% |
| SG&A Expense | $1.2M | — | +38.4% |
| Operating Income | -$2.3M | — | -23.3% |
| Net Income | -$2.2M | — | -39.0% |
| EPS (Basic) | -$0.28 | — | +41.7% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.1M | +12.0% | +656.3% |
| Accounts Receivable | $431K | -32.9% | +23.0% |
| Current Assets | $12.7M | +10.5% | +513.8% |
| Total Assets | $14.7M | +8.7% | +253.3% |
| Current Liabilities | $756K | -29.9% | -60.2% |
| Stockholders' Equity | $14.0M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.1M | — | -37.6% |
| Financing Cash Flow | $3.4M | — | +62.0% |
| +516.4% |